Taiwan Liposome Company
Quick facts
Marketed products
- AmBisome
- DSP · Oncology
DSP is a liposomal doxorubicin formulation that delivers the chemotherapy agent doxorubicin within lipid nanoparticles to improve drug targeting and reduce systemic toxicity. - Liposomal Amphotericin B · Infectious Disease
Liposomal amphotericin B binds to ergosterol in fungal cell membranes, creating pores that disrupt membrane integrity and cause fungal cell death.
Phase 3 pipeline
- TLC590
TLC590 is a liposomal formulation designed to deliver its active pharmaceutical ingredient with improved pharmacokinetics and reduced systemic toxicity. - TLC599 · Oncology
TLC599 is a liposomal formulation of a chemotherapeutic agent.
Phase 2 pipeline
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: